Lexeo Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
LXEO$3.14+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets (unaudited)
Condensed Balance Sheets
(Unaudited, in thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $40,996 | $35,014 |
| Current portion of investments in U.S. Treasury securities | 81,768 | 86,504 |
| Prepaid expenses and other current assets | 5,029 | 4,603 |
| Total current assets | 127,793 | 126,121 |
| Non-current portion of investments in U.S. Treasury securities | - | 7,012 |
| Long-term investment | 3,390 | - |
| Restricted cash | 3,248 | 3,252 |
| Property and equipment, net | 1,230 | 1,028 |
| Lease right-of-use assets - finance | 1,220 | 1,460 |
| Lease right-of-use assets - operating | 6,963 | 8,069 |
| Total assets | $143,844 | $146,942 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $4,656 | $6,417 |
| Accrued expenses and other current liabilities | 9,900 | 13,759 |
| Current portion of lease liabilities - finance | 568 | 570 |
| Current portion of lease liabilities - operating | 2,147 | 2,100 |
| Total current liabilities | 17,271 | 22,846 |
| Non-current liabilities | ||
| Non-current portion of lease liabilities - finance | 454 | 817 |
| Non-current portion of lease liabilities - operating | 5,288 | 6,437 |
| Total liabilities | 23,013 | 30,100 |
| Commitments and contingencies (Note 11) | ||
| Stockholders' equity: | ||
| Common stock, $0.0001 par value, 500,000,000 shares authorized as of September 30, 2025; 54,935,477 shares issued and 54,934,275 shares outstanding as of September 30, 2025; 500,000,000 shares authorized as of December 31, 2024; 33,079,209 shares issued and 33,071,261 shares outstanding as of December 31, 2024 | 5 | 3 |
| Treasury stock, at cost, 3,827 common shares as of September 30, 2025 and as of December 31, 2024 | (17) | (17) |
| Additional paid-in capital | 479,969 | 397,132 |
| Accumulated other comprehensive gain (loss) | 89 | (103) |
| Accumulated deficit | (359,215) | (280,173) |
| Total stockholders' equity | 120,831 | 116,842 |
| Total liabilities and stockholders' equity | $143,844 | $146,942 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.